ArticleOncology letters2024
Efficacy of the CV‑MED regimen in treating extramedullary involvement of multiple myeloma: A case report.
Article in Oncology letters, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond the bone marrow: a review of therapeutic approaches for extramedullary disease in multiple myeloma and the significance of MRD assessment.Journal of medicine and life · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extramedullary progression of multiple myeloma (MM) is commonly associated with a poor prognosis. However, optimal management strategies have not yet been established for the treatment of extramedullary involvement in MM. The present study reports the case of a 59-year-old female patient with MM who experienced extramedullary progression after two cycles of first-line VRD (bortezomib, lenalidomide and dexamethasone) therapy. The patient achieved remission of the extramedullary lesion following treatment with an innovative CV-MED regimen, which includes chidamide, bortezomib, mitoxantrone hydrochloride liposome, etoposide and dexamethasone. Subsequently, the patient underwent autologous hematopoietic stem cell harvesting and maintenance therapy, and remains in a progression-free survival state. The present case suggests that a chemotherapy regimen incorporating mitoxantrone hydrochloride liposomes, chidamide and bortezomib could be a promising treatment strategy for managing extramedullary involvement in MM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.